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Hemophagocytic syndrome (HPS) is characterized by the activation of histiocytes with prominent hemophagocytosis in bone marrow
and other reticuloendothelial systems. It has two forms: primary and secondary. The precise pathogenesis of HPS is unclear but a dys-
regulation of macrophage–lymphocyte interactions with subsequent increases in the levels of both T-cell-derived and macrophage-
derived cytokines has been suggested. Cardinal symptoms of HPS are prolonged high fever, hepatosplenomegaly, cytopenias, lymphad-
enopathy and neurological symptoms. In this report, we present a case Systemic Lupus Erythematosus associated with HPS and acute
pancreatitis.
 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Hemophagocytic syndrome (HPS) is a clinicopathologi-
cal entity characterized by activation and proliferation of
benign macrophages with hemophagocytosis throughout
the reticuloendothelial system. Reactive HPS can be associ-
ated with numerous diseases including acute leukemia,
malignant lymphoma, infections (viral, bacterial, fungal,
and parasitic), and systemic autoimmune diseases (Wong
et al., 1991; Papo et al., 1999; Dhote et al., 2003).http://dx.doi.org/10.1016/j.jdds.2014.03.004
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A 31-year-old indonesian female presented to our der-
matology outpatient clinic at the king Fahd Hospital of
the University with a complaint of erythematous rash
aﬀecting both cheeks of one month duration. There was
a positive history of fever, fatigue, weight loss, abdominal
pain and diarrhea. The patient was admitted to the hospi-
tal. Upon admission she had low grade fever and hypoten-
sion. Systemic examination revealed two enlarged cervical
lymph nodes of 2 by 2 cm in diameter, splenomegally was
detected with no other organomegaly. Neurological exam-
inations were unremarkable and there were no signs of
joint involvement. Dermatological examination revealed
bilateral erythematous scaly slightly raised lesions aﬀecting
both cheeks with the nasal bridge (Fig. 1). Her white blood
cell count was 2200, hemoglobin 11.4 g/dl and platelet
count 89,000/ml. Reticulocyte index was low. DirectSaud University.
ommons.org/licenses/by-nc-nd/3.0/).
Fig. 2. Bone marrow trephine biopsy. Note two lymphocytes within
cytoplasm of phagocyte (arrow). H&E 1000.
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Fibrinogen was 358 mg/dl. Erythrocyte sedimentation rate
was increased to 92 and C-reactive protein was 17.2 mg/l
(NR < 5.0). Her levels of serum Alanine Aminotransferase
(ALT), Aspartate aminotransferase (AST), and lactate
dehydrogenase were 11, 24, and 159 which increased to
950, 258, and 3484. High levels of serum ferritin
(4864 ng/ml, NR: 2.20–178) and fasting triglycerides
(702 mg/dl, NR: 35–135) were detected. Antinuclear anti-
body titer was 1:320 of speckled pattern, antismith anti-
bodies were strongly positive while Anti-double stranded
DNA and rheumatoid factor were negative. Serum amylase
and lipase were129 U/l and 774 U/dl respectively which
increased to 905 and 12501. A skin biopsy for the facial
lesion was suggested but unfortunately the patient refused.
Based on these ﬁndings we managed the patient as a case of
systemic lupus erythematosus. During her hospitalization,
she developed generalized tonic clonic seizures for which
a metabolic and septic cause was ruled out. Bone marrow
aspirate revealed moderately hypercellular bone marrow
with increased megakaryocytes and mildly increased hemo-
phagocytic histiocytes (5% of bone marrow mononuclear
cells) which were engulﬁng both myeloid and erythroid
cells (Fig. 2). So the patient was ﬁnally diagnosed as a case
of systemic lupus erythematosus and acute pancreatitis
with HPS. She was started on high dose steroids in addition
to hydroxychloroquine and mycophenolate mofetil.
During her admission the patient developed status epi-
lepticus which was believed to be secondary to neurolupus
and was admitted to the intensive care unit. Her illness
course was further complicated by the development of sep-
sis and acute renal failure on top of existing lupus nephritis.
She was managed eﬀectively by methylprednisolone,
hydroxychloroquine, mycophenolate mofetil and plasma-
pheresis with proper antibiotics and antifungal. After
12 weeks, the patient improved and her skin lesions cleared
with postinﬂammatory hyperpigmentation with no
scarring.Fig. 1. Erythematous scaly raised lesions aﬀecting both cheeks and the
nasal bridge.3. Discussion
Hemophagocytic syndrome (HPS) was ﬁrst described in
1939 by Scott and Robb-Smith. It is characterized by the
activation of histiocytes with prominent hemophagocytosis
in bone marrow and other reticuloendothelial systems. It
has two forms primary and secondary. Primary HPS com-
prises a group of distinct genetic diseases resulting in
impaired immune cell function, and are typically fatal with-
out immunosuppressive therapy and bone marrow trans-
plantation. Secondary HPS may occur at any age, in the
setting of malignancy, autoimmune disease, drug hypersen-
sitivity reaction, or infection (Janka and Stadt, 2005;
Rouphael et al., 2007; Brastianos et al., 2006).
In 1995 and 1997, Kumakura et al., proposed a new dis-
ease entity called autoimmune-associated hemophagocytic
syndrome (AAHS) Kumakura et al., 2004. The precise
pathogenesis of HPS is unclear but a dysregulation of mac-
rophage–lymphocyte interactions with subsequent
increases in the levels of both T-cell-derived and macro-
phage-derived cytokines, particularly TNF-a, M-CSF
receptors, interleukin (IL)-1, IL-6, interferon gamma
(IFN)-g, sIL-2R, and soluble TNF receptors (sTNFRs),
leads to an intense systemic inﬂammatory reaction (Osugi
et al., 1997; Pringe et al., 2007).
Cardinal symptoms of HPS are prolonged high fever,
hepatosplenomegaly, cytopenias, lymphadenopathy and
neurological symptoms such as cranial nerve palsies or sei-
zures. Characteristic laboratory ﬁndings include high tri-
glycerides, ferritin, transaminases, bilirubin, and
decreased ﬁbrinogen. The hemophagocytosis can be seen
in the bone marrow, lymph nodes, liver and spleen
(Janka and Stadt, 2005; Rouphael et al., 2007). Active mac-
rophages with engulfed leucocytes, erythrocytes, platelets
and their precursor cells are the typical ﬁndings. In 2004,
Kumakura et al. suggested important points for the diag-
nosis of AAHS (Kumakura et al., 2004).
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1. Cytopenia (aﬀecting >2 of 3 lineages in the peripheral
blood and not caused by an aplastic or dysplastic bone
marrow).
2. Histiocytic hemophagocytosis in bone marrow or other
reticuloendothelial systems including spleen, liver or
lymph nodes. Active phase of underlying autoimmune
disease at the occurrence of hemophagocytosis.
3. Other reactive hemophagocytic syndrome such as virus
or malignancy-associated hemophagocytosis syndrome
is excludable trigger of AAHS, exclusion of an infectious
complication is very important for the establishment of
the appropriate therapeutic strategy (Pringe et al., 2007).
The concept of “cytokine storm,” is characterized by the
secretion of huge amounts of cytokines, including inter-
feron-g, interleukin (IL)-2, IL-12, IL-18, and tumor necro-
sis factor-a, by activated Th1 cells and macrophages
(Larroche and Mouthon, 2004; Osugi et al., 1997). In auto-
immune-related HPS, IL-18, a strong inducer of Th1 cyto-
kines, has been suggested (Larroche and Mouthon, 2004).
Immunosuppressive therapy is indicated when HPS
occurs during the course of active SLE. Administration
of IVIG and G-CSF (in cases of severe neutropenia) may
be indicated for supportive care (Kumakura et al., 2004;
Verbsky and Grossman, 2006). In a review of English-lan-
guage literature through MEDLINE, we have identiﬁed
two cases of HPS and acute pancreatitis with SLE and ours
is the third (Wong et al., 1991; Dhote et al., 2003; Qian and
Yang, 2007; Yoshida et al., 2009; Hagiwara et al., 2006;
Silva Dda et al., 2008; Elqatni et al., 2012; Abdallah
et al., 2005).
4. Conclusion
In this report we are emphasizing the possible occur-
rence of SLE, secondary HPS and acute pancreatitis in
patients who might have skin lesion as their main com-
plaint. Association of HPS and acute pancreatitis in acute
SLE is very rare. Besides, when unexplained cytopenia pro-
gresses during the course of autoimmune disease, the phy-
sician should be aware of the possibility of HPS.References
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